Neurofit (Co-CEOs Bin Jun-gil and Kim Dong-hyun), an artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, announced on the 2nd that it has signed a memorandum of understanding (MOU) with the International Registry for Alzheimer's Disease and Other Dementias Foundation (InRAD).
Through this agreement, the two organizations will strengthen their collaboration to establish global standards for clinical data related to Alzheimer's disease and dementia. Neurofit aims to integrate its AI-based brain imaging analysis technology into real-world clinical data environments, thereby enhancing its usability in clinical settings.
The two parties plan to pursue ▲enhancing MRI and PET imaging-based clinical workflows ▲collecting and integrating clinical imaging and quantitative data ▲verifying the clinical utility of AI-based diagnostic solutions ▲developing joint research and education programs. The collaboration will utilize Neurophet's key solutions, including 'Neurophet AQUA,' 'Neurophet AQUA AD,' and 'Neurophet SCALE PET.'
InRAD, an independent international non-profit foundation headquartered in the Netherlands, supports dementia researchers in accessing data in a standardized manner and operates a registry system for Alzheimer's disease and dementia, a data entry platform, and a collaborative research platform. This supports regulatory and payer decision-making and accelerates dementia research and treatment development.
InRAD is expanding its international activities, particularly with a board of directors comprised of internationally renowned scholars, including Professor Philip Scheltens, who established the MRI-based diagnostic criteria for Alzheimer's disease, the MTA Scale (Scheltens Scale). Professor Scheltens stated, "This collaboration will lower the barriers to collecting clinical data and provide practical assistance in patient treatment."
Neurofit Co-CEO Bin Jun-gil said, “This agreement will serve as an opportunity to increase the global clinical applicability and reliability of Neurofit’s AI-based brain imaging analysis solution,” and “We will contribute to making it easier for medical professionals and researchers around the world to utilize standardized dementia clinical data.”
- See more related articles
You must be logged in to post a comment.